Ardigen's news feed
July 9, 2020
Share news in:

Ardigen enters into research collaboration with CVC to apply Artificial Intelligence for identification of T-cell targets - press release

KRAKÓW, Poland and Auckland, New Zealand, Jul. 9, 2020 /PRNewswire/ — Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

Ardigen’s neoantigen prediction platform called ‘ArdImmune Vax’ employs state of the art bioinformatics and Artificial Intelligence to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies. This technology is also very well suited for the design of vaccines for infectious diseases. The core of the platform is a proprietary algorithm capable of predicting neoantigens’ probability to elicit an immune response. 

This joint research enables CVC to benefit from Ardigen’s vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response. Complementing humoral and cellular response in the vaccine design is expected to result in 2 strong lines of defense against the coronavirus. The approach is likely to be more effective than vaccines designed to create antibodies alone.

“We are thrilled to help global efforts to mitigate COVID-19 applying our breakthrough technology powered by Artificial Intelligence, reducing the vaccine design phase to a few weeks.” – Comments Janusz Homa, CEO of Ardigen.

Robert Feldman, CEO and Co-founder of CVC, adds: “CVC is excited to be working with Ardigen who are at the forefront of T-cell epitope design. The collaboration gives us the best chance of our product inducing an effective T-cell response against SARS-Cov-2”.

June 9, 2020

AACR poster -2

Microbial signatures of response to anti-PD1 therapy in metastatic melanoma patients
Sept. 23, 2020
Ardigen has received funding to accelerate its AI-driven TCR discovery platform for novel cell therapies
Go up